Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million over 3 Years for Development of Myelo001 as Treatment for Acute Radiation Syndrome
Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced that it has been awarded a 3-year development contract valued at up to $6…